Century Therapeutics
(NASDAQ) IPSC
Century Therapeutics Financials at a Glance
Market Cap
$434.66M
Revenue (TTM)
$0.00
Net Income (TTM)
-$107.78M
EPS (TTM)
-$1.11
P/E Ratio
-2.18
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Price
$2.48
Volume
672
Open
$2.35
Price
$2.48
Volume
672
Open
$2.35
Previous Close
$2.41
Daily Range
$2.18 - $2.50
52-Week Range
$0.44 - $3.04
Estimated Earnings Date
Aug 13, 2026
Dividend
$0.00
Beta (Volatility)
1.39 (Average)
Price
$2.48
Volume
672
Open
$2.35
Previous Close
$2.41
Daily Range
$2.18 - $2.50
52-Week Range
$0.44 - $3.04
Estimated Earnings Date
Aug 13, 2026
IPSC News
IPSC: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Century Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
78
CEO
Brent Pfeiffenberger, PharmD
Website
www.centurytx.comHeadquarters
Philadelphia, PA 19104, US
IPSC Financials
Key Financial Metrics (TTM)
Gross Margin
0.00%
Operating Margin
0.00%
Net Income Margin
0.00%
Return on Equity
-53.23%
Return on Capital
-7.43%
Return on Assets
-33.01%
Earnings Yield
-45.87%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$434.66M
Shares Outstanding
180.35M
Volume
672
Avg. Volume
1.24M
Financials (TTM)
Gross Profit
-$29.86M
Operating Income
-$116.94M
EBITDA
-$89.90M
Operating Cash Flow
-$94.50M
Capital Expenditure
-$1.41M
Free Cash Flow
-$95.91M
Cash & ST Invst.
$134.80M
Total Debt
$48.03M
Century Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$0.00
-100.0%
Gross Profit
-$3.00M
-102.8%
Gross Margin
0.00%
N/A
Market Cap
$434.66M
N/A
Market Cap/Employee
$3.10M
N/A
Employees
140
N/A
Net Income
-$21.65M
-128.3%
EBITDA
-$18.64M
-123.4%
Quarterly Fundamentals
Total Cash
$134.80M
-18.4%
Total Debt
$48.03M
-8.8%
Accounts Receivable
$0.00
-100.0%
Inventory
$0.00
N/A
Long Term Debt
$43.94M
-8.1%
Short Term Debt
$4.08M
-16.4%
Return on Assets
-33.01%
N/A
Return on Invested Capital
-37.36%
N/A
Free Cash Flow
-$25.83M
+26.4%
Operating Cash Flow
-$25.24M
+27.1%